China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by China’s volume-based procurement (VBP) program....

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor...

Sanofi to acquire Origimm Biotechnology in a bid to expand vaccine pipeline

Sanofi will acquire Origimm Biotechnology as per an agreement signed by the two healthcare companies. The deal is expected to be finalized...

Is Biogen’s Alzheimer’s drug worth $56K? Experts say $8400 and raise questions about efficacy

Aduhelm, Biogen’s new drug for Alzheimer’s disease, which was approved by FDA contentiously last month, continues to face criticism since then.

AstraZeneca and FibroGen hit FDA committee’s safety data firewall for roxadustat

Two roxadustat partners AstraZeneca and FibroGen have received objections regarding safety concerns of their drug from the FDA after which the two companies

NRx Pharmaceuticals signs deal for clinical trials of Israel’s homegrown Covid-19 vaccine

Israel Institute for Biological Research (IIBR), an institute run by Israel’s Defense Ministry, has signed a memorandum of understanding (MoU) with the NRx Pharmaceuticals

Pharma manufacturers lawsuits against payers and benefit managers preferred drugs are on FTC’s radar

The attention of federal antitrust regulators has been drawn to a slew of lawsuits filed by pharmaceutical companies, challenging the “preferred” medicine list of payers and benefit managers.

Roche to lay off 300 to 400 employees in product development jobs

Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Takeda Pharmaceutical gets FDA nod for lung cancer drug Exkivity

The U.S. Food and Drug Administration had...

FDA approves first-ever at-home test for both COVID and Flu

The first over-the-counter, at-home test that can...

Raleigh-based specialty pharma company BDSI To Be Acquired By Collegium Pharma for $604m

Collegium Pharmaceutical has its eyes on taking over all outstanding shares of BDSI for $604 million or at the rate of $5.60 per share of BioDelivery stock price.